PMID- 35299739
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220319
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Cystic Neoplasms of the Pancreas: Differential Diagnosis and Radiology 
      Correlation.
PG  - 860740
LID - 10.3389/fonc.2022.860740 [doi]
LID - 860740
AB  - Although the probability of pancreatic cystic neoplasms (PCNs) being detected is 
      raising year by year, their differential diagnosis and individualized treatment 
      are still a challenge in clinical work. PCNs are tumors containing cystic 
      components with different biological behaviors, and their clinical 
      manifestations, epidemiology, imaging features, and malignant risks are 
      different. Some are benign [e.g., serous cystic neoplasms (SCNs)], with a barely 
      possible that turning into malignant, while others display a low or higher 
      malignant risk [e.g., solid pseudopapillary neoplasms (SPNs), intraductal 
      papillary mucinous neoplasms (IPMNs), and mucinous cystic neoplasms (MCNs)]. PCN 
      management should concentrate on preventing the progression of malignant tumors 
      while preventing complications caused by unnecessary surgical intervention. 
      Clinically, various advanced imaging equipment are usually combined to obtain a 
      more reliable preoperative diagnosis. The challenge for clinicians and 
      radiologists is how to accurately diagnose PCNs before surgery so that 
      corresponding surgical methods and follow-up strategies can be developed or not, 
      as appropriate. The objective of this review is to sum up the clinical features, 
      imaging findings and management of the most common PCNs according to the classic 
      literature and latest guidelines.
CI  - Copyright (c) 2022 Hu, Hu, Wang, Ma, Yue, Tang, Liu, Wu, Peng and Tong.
FAU - Hu, Feixiang
AU  - Hu F
AD  - Department of Radiology, Fudan University Shanghai Cancer Center, Department of 
      Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
FAU - Hu, Yue
AU  - Hu Y
AD  - Hefei Cancer Hospital, Chinese Academy of Sciences (CAS), Hefei, China.
FAU - Wang, Dan
AU  - Wang D
AD  - Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, China.
FAU - Ma, Xiaowen
AU  - Ma X
AD  - Department of Radiology, Fudan University Shanghai Cancer Center, Department of 
      Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
FAU - Yue, Yali
AU  - Yue Y
AD  - Children's Hospital, Fudan University, Shanghai, China.
FAU - Tang, Wei
AU  - Tang W
AD  - Department of Radiology, Fudan University Shanghai Cancer Center, Department of 
      Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
FAU - Liu, Wei
AU  - Liu W
AD  - Department of Radiology, Fudan University Shanghai Cancer Center, Department of 
      Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
FAU - Wu, Puye
AU  - Wu P
AD  - General Electric (GE) Healthcare, Shanghai, China.
FAU - Peng, Weijun
AU  - Peng W
AD  - Department of Radiology, Fudan University Shanghai Cancer Center, Department of 
      Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
FAU - Tong, Tong
AU  - Tong T
AD  - Department of Radiology, Fudan University Shanghai Cancer Center, Department of 
      Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220301
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8921498
OTO - NOTNLM
OT  - intraductal papillary mucinous neoplasms (IPMNs)
OT  - mucinous cystic neoplasms (MCNs)
OT  - pancreatic cystic neoplasms (PCNs)
OT  - radiology
OT  - serous cystic neoplasms (SCN)
OT  - solid pseudopapillary neoplasms (SPN)
COIS- Author PW was employed by GE Healthcare. The remaining authors declare that the 
      research was conducted in the absence of any commercial or financial 
      relationships that could be construed as a potential conflict of interest.
EDAT- 2022/03/19 06:00
MHDA- 2022/03/19 06:01
PMCR- 2022/01/01
CRDT- 2022/03/18 05:09
PHST- 2022/01/23 00:00 [received]
PHST- 2022/02/04 00:00 [accepted]
PHST- 2022/03/18 05:09 [entrez]
PHST- 2022/03/19 06:00 [pubmed]
PHST- 2022/03/19 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.860740 [doi]
PST - epublish
SO  - Front Oncol. 2022 Mar 1;12:860740. doi: 10.3389/fonc.2022.860740. eCollection 
      2022.